Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT02222727
Other study ID # 13.0099
Secondary ID 2013-002457-30
Status Terminated
Phase Phase 2
First received August 20, 2014
Last updated September 8, 2017
Start date January 2014
Est. completion date November 2016

Study information

Verified date September 2017
Source St George's, University of London
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Introduction

Aneurysmal subarachnoid hemorrhage (aSAH) is bleeding around the under surface of the brain caused by rupture of an aneurysm arising from a blood vessel. Stroke may occur in approximately one third of patients as a result of narrowing of the blood vessels around the brain, following aSAH.

One theory as to why this may happen is because bleeding around the base of the brain damages particular cells (neurons) that control blood flow around the rest of the brain. These neurons may control blood flow by releasing a neurotransmitter called Acetyl Choline (ACh). Our hypothesis is that damage to these neurons may prevent the production of ACh, which then causes reduced blood flow and stroke if left untreated.

By stimulating these neurons, we aim to investigate whether it is possible to improve the blood flow around brain and ultimately prevent strokes in patients following subarachnoid haemorrhage. Donepezil, a drug widely used in dementia, inhibits the brain's natural break down of ACh. We predict that by increasing the amount of Ach in these neurons, donepezil may improve blood flow to the brain, reducing the chance of developing stroke.

Trial Protocol

All patients admitted to St George's hospital with a confirmed aneurysmal subarachnoid haemorrhage between the ages of 18 and 85 years old will be invited to participate in the trial. The protocol has been designed to take place around the patients' aneurysm treatment, which is performed under general anesthesia (GA). Recruited participants will be anesthetized for their aneurysm treatment and then enter the study.

All trial participants will have a Xenon CT scan under GA to assess brain blood flow prior to having treatment of their aneurysm. Patients randomized to donepezil treatment will receive a loading dose of 20mg via a feeding tube immediately after their Xenon scan. Patients in the control group will not receive the drug.

All patients in the trial will undergo repeat Xenon perfusion scanning under GA between 3 and 4 hours after their first scan, which coincides with the completion of their aneurysm treatment. Those in the donepezil group will then receive a daily dose of 5 mg for a period of 21 days.

All aspects of care other than those related to the trial will be the same as for any other subarachnoid haemorrhage patients. Patients (or their legal representative for those unable to consent) will be able to decline participation in the trial or withdraw at any point.


Recruitment information / eligibility

Status Terminated
Enrollment 19
Est. completion date November 2016
Est. primary completion date November 2016
Accepts healthy volunteers No
Gender All
Age group 18 Years to 85 Years
Eligibility Inclusion Criteria:

- age 18 - 85 years

- Fisher score 2-4

- recruitment within 12 - 72 hours of hemorrhage

Exclusion Criteria:

- pregnancy

- breast feeding

- allergy to donepezil or other piperidine derivatives

- participants unwilling to use appropriate birth control up to 6 weeks after enrolment

- known dementia

- severe liver failure (Child-Pugh C)

- sick sinus syndrome or other supraventricular cardiac conduction abnormalities

- inspired oxygen requirement greater than 60%

- history of brittle asthma or obstructive airway disease

- aneurysm unsuitable for endovascular coiling

- concomitant use of cholinesterase inhibitor (e.g. rivastigmine, galantamine, etc)

Study Design


Intervention

Drug:
Donepezil
Loading 20 mg dose of donepezil on first day of recruitment followed by once daily 5 mg dose for subsequent twenty days

Locations

Country Name City State
United Kingdom St George's University of London London

Sponsors (1)

Lead Sponsor Collaborator
St George's, University of London

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Cerebral blood flow Baseline xenon perfusion CT (XeCTP) scan performed immediately before donepezil loading dose administered. Follow-up XeCTP scan minimum of 3 hours after loading dose.
For control group patients, baseline XeCTP scan performed before aneurysm treatment and follow-up scan 3-4 hours after first scan.
Within 3-4 hours of receiving drug
Secondary Number of participants with adverse events. Participants receiving donepezil will continue to take for 21 days in total and the washout period for the drug is approximately 2 weeks accounting for a total evaluation period of 5-6 weeks.
All participants will be regularly evaluated by clinical staff while inpatients under care of the neurosurgical service. Those discharged prior to the 6 week period will be followed up regularly by telephone and provided with a diary to record potential adverse events.
6 weeks from enrolment
Secondary Disability assessment All participants will have a modified Rankin Score (mRS) at 6 months to assess their level of disability in comparison with their status on enrolment. 6 months from enrolment
See also
  Status Clinical Trial Phase
Completed NCT03209830 - Pharmaceutical Treatment of Fatigue After Aneurysmal Subarachnoid Hemorrhage Phase 2
Completed NCT05131295 - Dapsone Use in Patients With Aneurysmal Subarachnoid Hemorrhage. Phase 3
Recruiting NCT04583163 - Variability in Transcranial Doppler Technique in Neuro-Critical Care Patients
Not yet recruiting NCT03271697 - Astragalus Membranaceus on Aneurysmal Subarachnoid Hemorrhage Phase 2/Phase 3
Recruiting NCT01098890 - Intraventricular Tissue Plasminogen Activator (tPA) in the Management of Aneurysmal Subarachnoid Hemorrhage Phase 2
Completed NCT00692744 - Quality of Life in Elderly After Aneurysmal Subarachnoid Hemorrhage (SAH) N/A
Active, not recruiting NCT05738083 - Prediction Models for Complications, Disability, and Death in Patients With Aneurysmal Subarachnoid Hemorrhage
Completed NCT03754335 - SubArachnoid Hemorrhage HEadache Treated by Lumbar Puncture N/A
Completed NCT06076590 - Impact of Multiple Electrolytes Injection Ⅱ and Saline on Hyperchloremia in Patients With Aneurysmal Subarachnoid Hemorrhage:a Pilot Study Phase 4
Recruiting NCT04548401 - Effect of Antiplatelet Therapy on Cognition After Aneurysmal Subarachnoid Hemorrhage
Terminated NCT04148105 - Cilostazol and Nimodipine Combined Therapy After Aneurysmal Subarachnoid Hemorrhage (aSAH) Phase 4
Recruiting NCT06329635 - Treatment of Vasospasm of Aneurysmal Subarachnoid Hemorrhage With Intrathecal Nicardipine - FAST-IT Trial N/A
Recruiting NCT02129413 - Safety Study of Carotid Body Neurostimulation to Treat Cerebral Vasospasm N/A
Terminated NCT00487461 - Use of Simvastatin for the Prevention of Vasospasm in Aneurysmal Subarachnoid Hemorrhage N/A
Recruiting NCT06288659 - aSAH Treatment Based on Intraventricular ICP Monitoring: A Prospective, Multicenter, Randomized and Controlled Trial N/A
Recruiting NCT05974111 - COAgulation Disorders in Ischaemic and Haemorrhagic Stroke
Recruiting NCT03706768 - Degradation of the Glycocalyx in Delayed Cerebral Ischemia After Aneurysmal Subarachnoid Hemorrhage N/A
Recruiting NCT06284642 - Early Lumbar Drainage Combined With Intrathecal Urokinase Injection for Treatment of Severe Aneurysmal SAH (LD-ITUK) Phase 4
Recruiting NCT01773200 - Prognostic Value of Circulating Endothelial Progenitor Cells in Aneurysmal Subarachnoid Hemorrhage N/A
Completed NCT02026596 - SpareBrain - Mechanisms and Prevention of Secondary Brain Injury in Subarachnoid Haemorrhage N/A